This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Fresenius Kabi Oncology Limited. Active years: 2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2018
Title: Vikas Chandel: Innovator in Pharmaceutical Compositions
Introduction
Vikas Chandel is a notable inventor based in Gurgaon, India. He has made significant contributions to the field of pharmaceuticals, particularly in developing stable compositions of compounds that are susceptible to hydrolysis. His work is essential for enhancing the efficacy and stability of pharmaceutical products.
Latest Patents
Vikas Chandel holds a patent for a process titled "Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis." This invention outlines a method that includes the addition of pharmaceutically acceptable lyophilization excipients, the use of organic solvents, and specific temperature controls to create stable pharmaceutical formulations. The process aims to ensure the stability of compounds that are prone to hydrolysis, which is crucial for their effectiveness in medical applications.
Career Highlights
Vikas Chandel is currently employed at Fresenius Kabi Oncology Limited, where he applies his expertise in pharmaceutical development. His innovative approach to creating stable formulations has positioned him as a valuable asset in the industry. His work not only contributes to the advancement of pharmaceutical sciences but also enhances patient care through improved medication stability.
Collaborations
Vikas collaborates with several professionals in his field, including Dhiraj Khattar and Rajesh Khanna. These collaborations foster a dynamic environment for innovation and development in pharmaceutical research.
Conclusion
Vikas Chandel's contributions to the pharmaceutical industry through his innovative patent demonstrate his commitment to improving drug stability and efficacy. His work is vital for the ongoing advancement of pharmaceutical sciences and patient care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
